Image of The Use of Mind-Altering Substances: MDMA, Psilocybin, and Marijuana f
Digital Seminar

The Use of Mind-Altering Substances: MDMA, Psilocybin, and Marijuana for Treating PTSD and Other Mental Distress *Pre-Order*


Faculty:
Michael Mithoefer |  Bessel Van der Kolk |  Richard C. Schwartz |  Rick Doblin |  William Richards |  Daniel McQueen |  James W. Hopper |  Anne St. Goar |  Elizabeth Call |  Susan Walker |  Francis Guerriero |  Michael Alpert
Duration:
6 Hours 28 Minutes
Format:
Audio and Video
Copyright :
May 29, 2019
Product Code:
POS052628
Media Type:
Digital Seminar


Description

This digital seminar is currently on pre-order meaning that the video will not be ready until 10-12 weeks after the program has taken place.

For the first time in over four decades, researchers are returning to examining the therapeutic benefits of mind altering substances, including MDMA (ecstasy), psilocybin (mushrooms), marijuana and LSD.

In the 1970s the study of all psychedelics was criminalized in the US, despite emerging evidence of their medical value. Over the past decade, the Multidisciplinary Association for Psychedelic Research (MAPS) has helped to revive psychedelic research, sponsoring studies across the United States and around the world, including MDMA-assisted therapy for PTSD, and end-of-life anxiety. The results have been very positive, lasting over 72 months of follow-up, with few adverse effects.

Psychedelics may promote a deepening and acceleration of the psychotherapeutic process. During therapy, people often are able to access and find peace with disavowed, “exiled” parts of themselves.

In this workshop recording the founder of MAPS will describe the evolution of psychedelic therapy, the principal investigator of the Phase I and II level trials will discuss outcomes and processes, the PI of the Hopkins psilocybin study terminally ill patients and a marijuana researcher the promises and pitfalls for that substance. The Boston MDMA study team will discuss clinical experiences and applications.

In appropriate therapeutic contexts, psychedelics may prove to be more effective than most conventional treatments, as well as safer and more cost-effective.

Credits


CE Information Coming Soon

Continuing education credit information is coming soon for this non-interactive self-study package.

CEs may be available for select professions, as listed in the target audience. Hours will be dependent on the actual recording time. Please check with your state licensing board or organization for specific requirements. 

There may be an additional fee for CE certificates. Please contact our Customer Service at 1-800-844-8260 for more details. 

**Materials that are included in this course may include interventions and modalities that are beyond the authorized practice of mental health professionals. As a licensed professional, you are responsible for reviewing the scope of practice, including activities that are defined in law as beyond the boundaries of practice in accordance with and in compliance with your professions standards.



Handouts

Faculty

Michael Mithoefer Related seminars and products: 2

MD


Michael Mithoefer, MD, clinical assistant professor of psychiatry at the Medical University of South Carolina. In 2009, he completed & published the first FDA approved clinical trial of MDMA assisted psychotherapy for treatment-resistant PTSD, followed by completion of a Phase II trial. He is overseeing a multisite Phase III study of MDMA-assisted psychotherapy in 13 sites around the US (including the Trauma Research Foundation), and another MDMA-assisted psychotherapy multisite study in Europe and Israel.

Speaker Disclosures:

Financial: Michael Mithoefer receives a salary and grants from MAPS Public Benefit Corp and is a clinical assistant professor at the Medical University of South Carolina.

Non-financial: Michael Mithoefer is a member of the non-profit MAPS.

 


Bessel Van der Kolk Related seminars and products: 34

M.D.


Bessel A. Van der Kolk, M.D., is a clinician, researcher and teacher in the area of post-traumatic stress.  His work integrates developmental, neurobiological, psychodynamic and interpersonal aspects of the impact of trauma and its treatment.

Dr. van der Kolk and his various collaborators have published extensively on the impact of trauma on development, such as dissociative problems, borderline personality and self-mutilation, cognitive development, memory, and the psychobiology of trauma.  He has published over 150 peer reviewed scientific articles on such diverse topics as neuroimaging, self-injury, memory, neurofeedback, Developmental Trauma, yoga, theater and EMDR. 

He is founder and medical director of the Trauma Center in Brookline, Massachusetts.  The Trauma Center consists of a well-trained clinical team specializing in the treatment of children and adults with histories of child maltreatment, that applies treatment models that are widely taught and implemented nationwide.  He also created the Trauma Research Foundation, the non-profit arm of the Trauma Center, that is organized to promote clinical, scientific and educational projects.

His most recent 2014 New York Times best seller, The Body Keeps the Score: Brain, Mind, and Body in the Treatment of Trauma, transforms our understanding of traumatic stress, revealing how it literally rearranges the brain’s wiring – specifically areas dedicated to pleasure, engagement, control, and trust.  He shows how these areas can be reactivated through innovative treatments including neurofeedback, somatically based therapies, EMDR, psychodrama, play, yoga, and other therapies.

Dr. van der Kolk is the past president of the International Society for Traumatic Stress Studies, and professor of psychiatry at Boston University Medical School.  He regularly teaches at conferences, universities, and hospitals around the world.

Speaker Disclosures:

Financial: Bessel van der Kolk is a professor of psychiatry at the Boston University School of Medicine.  He receives a speaking honorarium from PESI, Inc. 
Nonfinancial:  Bessel van der Kolk has no relevant nonfinancial relationship to disclose.


Richard C. Schwartz Related seminars and products: 12

Ph.D., Owner

The Center for Self Leadership


Richard Schwartz, Ph.D., earned his Ph.D. in marriage and family therapy from Purdue University, after which he began a long association with the Institute for Juvenile Research at the University of Illinois at Chicago, and more recently at The Family Institute at Northwestern University, attaining the status of associate professor at both institutions. He is co-author, with Michael Nichols, of Family Therapy: Concepts and Methods, the most widely used family therapy text in the United States.

Dr. Schwartz developed Internal Family Systems in response to clients’ descriptions of experiencing various parts – many extreme – within themselves. He noticed that when these parts felt safe and had their concerns addressed, they were less disruptive and would accede to the wise leadership of what Dr. Schwartz came to call the “Self.” In developing IFS, he recognized that, as in systemic family theory, parts take on characteristic roles that help define the inner world of the clients. The coordinating Self, which embodies qualities of confidence, openness, and compassion, acts as a center around which the various parts constellate. Because IFS locates the source of healing within the client, the therapist is freed to focus on guiding the client’s access to his or her true Self and supporting the client in harnessing its wisdom. This approach makes IFS a non-pathologizing, hopeful framework within which to practice psychotherapy. It provides an alternative understanding of psychic functioning and healing that allows for innovative techniques in relieving clients symptoms and suffering.

In 2000, Richard Schwartz founded The Center for Self Leadership in Oak Park, Illinois. Dr. Schwartz is a featured speaker for many national psychotherapy organizations and a fellow of the American Association for Marriage and Family Therapy, and he serves on the editorial boards of four professional journals. He has published four books and over 50 articles about IFS. His books include Internal Family Systems Skills Training Manual (with Frank Anderson, M.D. and Martha Sweezy, Ph.D) (PESI, 2017), Internal Family Systems Therapy (Guilford Press, 1997), Introduction to the Internal Family Systems Model (Tarcher, 2001), and The Mosaic Mind (with Regina Goulding) (Trailheads, 2003), as well as Metaframeworks (with Doug Breunlin and Betty Karrer) (Jossey-Bass, 1997). Dr. Schwartz lives and practices in Brookline, MA and is on the faculty of the Department of Psychiatry, Harvard School of Medicine.

Speaker Disclosures:

Financial: Richard Schwartz is the Founder of The Center for Self Leadership. He receives a speaking honorarium from PESI, Inc.

Non-financial: Richard Schwartz is a Fellow and member of the American Association for Marital and Family Therapy.


Rick Doblin Related seminars and products: 1

Ph.D.


Rick Doblin, Ph.D., Executive Director, Multidisciplinary Association for Psychedelic Studies (MAPS); chair of the board of directors MAPS Public Benefit Corporation.


William Richards Related seminars and products: 1

Ph.D.


William Richards, Ph.D., Psychologist, Johns Hopkins Bayview Medical Center where he is co-director of the program in psilocybin for terminally ill cancer patients. Contributor Fantastic Fungi.


Daniel McQueen Related seminars and products: 1

MA


Daniel McQueen, MA, Psychedelic therapist and executive director of Medicinal Mindfulness.  Author of Cannabis-Assisted Psychedelic Therapy for Trauma Resolution.


James W. Hopper Related seminars and products: 2

Ph.D.


James W. Hopper, Ph.D., Independent consultant and instructor in psychology, Cambridge Health Alliance & Harvard Medical School. Co-editor, Mindfulness-oriented interventions for trauma: Integrating contemplative practices. The MDMA Team, Trauma Research Foundation.


Anne St. Goar Related seminars and products: 1

MD


Anne St. Goar, MD, Primary care physician at HVMA, emeritus certified psychedelic therapist; Boston MDMA Therapy team member with the Trauma Research Foundation.


Elizabeth Call Related seminars and products: 1

Psy.D.


Elizabeth Call, Psy.D., Psychologist in private practice. Therapy team member, MDMA study, the Trauma Research Foundation.


Susan Walker Related seminars and products: 1

MD


Susan Walker, MD, Instructor in psychiatry, Harvard Medical School.  Child and Adolescent Psychiatrist, Cambridge Health Alliance. MDMA Therapy Team Member, the Trauma Research Foundation.


Francis Guerriero Related seminars and products: 1

MA, LICSW


Francis Guerriero, MA, LICSW, Private practice, Cambridge, MA; MDMA Therapy team member, The Trauma Research Foundation.


Michael Alpert Related seminars and products: 1

MD


Michael D. Alpert, MD, Psychiatrist, South Cove Community Health Center, Boston Harvard Medical School; MDMA Therapy team member, the Trauma Research Foundation.


Additional Info

Program Information

CD/DVD

Click here to purchase the DVD or CD recording from our product store. CE hours and approvals on products may differ from live CE approvals.


Access for Self-Study (Non-Interactive)

Access never expires for this product.


Objectives

  1. Identify how the emerging research of MDMA-assisted psychotherapy (MDMA-AP) can be an effective for clients who do not respond to traditional therapies for PTSD.
  2. Distinguish how prolonged exposure (PE) therapy can be ineffective for some clients, and recognize how MDMA-AP decrease client dropout rates.
  3. Summarize the mechanism of MDMA in the brain and how that relates to the treatment of trauma.
  4. Examine the therapeutic benefits of psychedelic substances, including MDMA (ecstasy), psilocybin (mushrooms) and LSD.
  5. Identify the positive effects on PTSD symptom severity by the end of the first treatment trial.
  6. Discover how psychedelics may promote a deepening and acceleration of the psychotherapeutic process for clients.
  7. Evaluate the research regarding phase I & II trials involving MDMA.
  8. Evaluate the potential risks of MDMA-AP, including substance abuse and neurocognitive decline.

Outline

Evolution of Psychedelic Therapy

  • MDMA – ecstasy
  • Psilocybin – mushrooms
  • LSD

Why Study MDMA-assisted Therapy for PTSD

Clinical Trials

Phase I & II Trials

  • Process
  • Outcomes
  • Potential risks and benefits

PTSD - Boston’s MDMA Study Team

  • Clinical experiences
  • Applications

IFS + MDMA Research Studies

Integration of MDMA

Therapist-Client Relationship

Keys to Work Safely with Trauma Clients

Questions/Comments

Target Audience

  • Social Workers
  • Counselors
  • Psychologists
  • Physicians
  • Psychiatrists
  • Addiction Counselors
  • Marriage & Family Therapists
  • Occupational Therapists
  • Occupational Therapy Assistants
  • Nurses
  • Other Mental Health Professionals

Reviews

Satisfaction Guarantee
Your satisfaction is our goal and our guarantee. Concerns should be addressed to: PO Box 1000, Eau Claire, WI 54702-1000 or call 1-800-844-8260.

ADA Needs

We would be happy to accommodate your ADA needs; please call our Customer Service Department for more information at 1-800-844-8260.

Please wait ...

Back to Top